日韩成人一区二区三区在线观看,亚洲爆乳成av人在线视菜奈实,一级特黄aaa大片在线观看成人一级片在线观看,欧美一级a视频在线观看,久久综合狠狠色综合伊人,国产亂倫近親相姦视频,日韩免费无码视频一区二区三区,97久久精品亚洲中文字幕无码,久爱无码精品免费视频,超碰97人人模人人爽人人

Recombinant Protein
Home > Application > Recombinant Protein > Insulin

Insulin


Diabetes is a global disease affecting more than 420 million people (6% of the world's population), a number that is expected to balloon to 500 million by 2030 and 700 million by 2045. The increase in the number of diabetic patients worldwide will lead to a consequent increase in the need for insulin. Furthermore, there is an unmet need for affordable insulin, especially in low- and middle-income countries. Many people with type 1 diabetes who live entirely on insulin do not have access to insulin. Of the 60 million people with type 2 diabetes who require insulin therapy, one in two do not have access to insulin because of price (WHO 2021).

 

Injectable insulin is important in the treatment of both type 1 and type 2 diabetes, and recombinant human insulin has been shown to offer significant advantages over extracted insulin. For the production of insulin, two different production methods have been reported. In the first method, the A and B chains of insulin are cultured separately in bacteria as inclusion bodies. Then, the two chains are purified separately, then chemically joined, followed by a final purification step. In the second technique, proinsulin is expressed in E. coli in the form of a tryptophan promoter with methionine linked to proinsulin. Cyanogen bromide (CNBr) is used to cleave the linkage, then form the folded peptide through the correct disulfide bonds, and finally enzymatically eliminate the C-peptide. The "proinsulin route" is preferred because it requires only a single fermentation and purification procedure, and the production process is more efficient compared to the two-chain combinatorial approach.

 

In addition to using bacteria as a host system, yeast is also used for the commercial production of insulin. The main yeast strains used commercially are Saccharomyces cerevisiae and Pichia pastoris. The yeast-based expression system produces a soluble insulin precursor that is secreted into the culture supernatant. There are pros and cons to using bacteria and yeast as expression systems. Production of precursor insulin via the bacterial inclusion body pathway generally results in higher product concentrations and productivity. Compared to soluble expression of bioactive therapeutic proteins, inclusion bodies have good mechanical stability and are resistant to proteolytic degradation. In terms of downstream purification, target proteins in inclusion bodies are also isolated in a purer and more concentrated state compared to secreted proteins, which require removal of large amounts of host cell protein impurities from culture supernatants. Peptides are also easier to isolate from inclusion bodies due to their different sizes and densities compared to host proteins.

 

The use of Escherichia coli as an expression system for large-scale recombinant insulin production has the advantages of high growth rate, simple media requirements, easy for operation, high yield, and cost-effectiveness. E. coli is also well characterized genetically, and a large number of mutant host strains and cloning vectors are available. However, the inclusion body production pathway in E. coli requires complex processing, such as solubilization and refolding procedures, to obtain fully functional polypeptides. For most biopharmaceutical companies, Escherichia coli remains the host system of choice for the production of recombinant insulin, with human insulin and its analogs expressed in inclusion bodies in most cases. Insulin analogs are synthetically produced variants of insulin whose amino acid sequence differs from native human insulin. Such changes have been made to more closely mimic the normal physiological pattern of insulin secretion in humans.

 

The single-chain insulin precursor molecule in E. Coli inclusion bodies was mostly misfolded. Inclusion bodies are extracted from cells, washed, and the precursor molecules are solubilized. The production of proinsulin requires peptide folding and the concomitant formation of disulfide bonds. After an enzymatic reaction, the refolded precursor molecule is converted into a heterodimeric insulin molecule by removal of the C-chain and N-terminal fusion peptide. Various chromatographic purification steps are required to remove host cell proteins, nucleic acids, membrane debris, and digestion by-products to yield highly purified products.

 

The downstream process for purification of recombinant human insulin/analogues from E. coli inclusion bodies is complex, involves multiple steps, and details of the processes established by different companies are often proprietary. The method used in each step will have a major impact on the product purity and yield in the next step, so in-depth consideration and research should be done during development and optimization.




None

None

Related Products
Contact Us
  • Tel.: +86 021 6434 0155
  • E-Mail: marketing@duoningbio.com
  • Address: Building 30, No. 1525 Minqiang Road, Songjiang District, Shanghai
Message

Copyright ? Shanghai Duoning Biotechnology Co., Ltd. All Rights Reserved Sitemap | Technical Support: Reanod

WeChat
WeChat

Message-

Duoning Biotechnology

+86 021 6434 0155

亚洲AV女人18毛片水真多| 18禁无遮挡羞羞污污污污免费| 无码人妻久久一区二区三区蜜桃| 国产老妇伦国产熟女老妇视频| 欧美黑人又大又粗XXXⅩ| 午夜A理论片在线播放| 成人亚洲欧美在线电影www色| 精品乱子伦一区二区三区高清免费播放| 精品国精品国产自在久久| 无码国产色欲XXXXX视频| 尤物蜜芽视频在线观看国产| 中文字幕精品无码亚洲幕| 中国少妇的bbb真爽| 人人妻人人爽人人做夜欢视频九色| 久久精品亚洲中文字幕无码网站| 婷婷蜜桃国产精品一区| 无套内谢少妇毛片免费看| 美国一级真人片在线观看| 影音先锋熟女少妇AV资源| 亚洲欧美成人AⅤ在线专区| 久久精品亚洲中文字幕无码网站| 午夜成人爽爽爽视频在线观看| 免费看女人与公拘交酡过程| 少妇AV射精精品蜜桃专区| 国产日韩久久久免费影院| 婷婷丁香综合五月久久综合| 国产成人精品黄色视频| 内射人妻无码色AV天堂| 午夜伦4480YY私人影院久久| 四虎国产精品永久在线| 成全免费看高清电影| 国产成人一区二区三区视频免费| 亚洲综合精品香蕉久久网97| 国产A∨国片精品青草视频| 中文字幕精品一区二区三区| 久久久久精品国产三级| 中文字幕亚洲欧美无线码一区| AV伊人久久综合一区二区三区| 无码精品不卡一区二区三区| 公女乱小说视频在线观看| 天天躁日日躁狠狠躁视频2021|